High levels of the Wilms' Tumor 1 (WT1) protein and mRNA had been associated with aggressive phenotypes of breast tumors. Here we report that the HER2/neu oncogene increases WT1 expression. Approximately threefold higher levels of WT1 protein were observed in MCF-7 breast cancer cells transfected with the HER2/ neu oncogene than in parental MCF-7 cells. Conversely, inhibition of HER2/neu with the anti-HER2/neu trastuzumab (Herceptint) antibody decreased WT1 protein levels in HER2/neu-overexpressing BT-474 and SKBr3 cells. We also found that HER2/neu engages Akt to regulate WT1 levels since inhibition of Akt reduced WT1 levels. Decreased expression of WT1 protein led to cell cycle arrest at the G1 phase and increased apoptosis in HER2/neu-overexpressing cells, which is correlated with decreased cyclin D1 and Bcl-2 levels. Our data indicate that HER2/neu engages Akt to increase WT1 expression, and that WT1 protein plays a vital role in regulating cell cycle progression and apoptosis in HER2/neu-overexpressing breast cancer cells.
The Wilms' tumor 1 (WT1) gene was originally identified as a tumor suppressor gene responsible for Wilms' tumor Haber et al., 1990) . In addition to germ-line mutations, somatic mutations of WT1 as well as loss of heterozygosity at the 11p13 locus harboring WT1 have been reported in sporadic Wilms' tumors. WT1 is a transcription factor that binds to CGand TCC-rich sequences on promoters of target genes (Lee and Haber, 2001) . High levels of the wild-type WT1 mRNA had been found in leukemias (Inoue et al., 1997) , lung tumors (Oji et al., 2002) , and breast tumors . WT1 expression had been associated with the more biologically aggressive phenotypes of breast tumors, such as estrogen receptor (ER) negativity and tumors >2 cm (Silberstein et al., 1997) .
Patients with high WT1 mRNA levels in their breast tumors were found to have a lower 5-year disease-free survival rate than patients whose breast tumors expressed low WT1 mRNA levels . These data strongly suggest that WT1 expression is vital to breast cancer, perhaps especially in the aggressive phenotypes. However, it is not known what factors in the aggressive breast tumors cause higher WT1 expression levels, and the functions of WT1 protein in such tumors.
Amplification of the HER2/neu oncogene is found in 30% of human breast cancers and is associated with poorer survival in breast cancer patients (Slamon et al., 1987) . HER2/neu-overexpressing breast tumors are of the aggressive phenotype and are likely to be ER negative (Adnane et al., 1989) . Thus, HER2/neu may be one factor that increases WT1 levels. Here we show that HER2/neu engages Akt to increase WT1 expression, and that WT1 protein stimulates G1/S-phase cell cycle progression and inhibits apoptosis in HER2/neu-overexpressing breast cancer cells, possibly via cyclin D1 and Bcl-2 proteins.
Results and discussion

HER2/neu increases WT1 protein expression in breast cancer cells
Higher levels of WT1 protein were observed in BT-474, MDA-MB-453, and SKBr3 breast cancer cell lines than in MDA-MB-231 cells ( Figure 1a ). All cell lines except, MDA-MB-231, express high levels of the HER2/neu protein ( Figure 1a) . Thus, we speculate that HER2/neu increases WT1 expression in breast cancer cells. The levels of WT1 protein were compared between MCF-7 cells transfected with the HER2/neu gene (MCF-7/ HER2) and parental MCF-7 cells. Approximately three fold higher levels of WT1 protein were observed in MCF-7/HER2 cells than in parental MCF-7 cells (Figure 1a ). To further prove that HER2/neu increases WT1 protein expression, trastuzumab was used to inhibit HER2/neu function. SKBr3 and BT-474 breast cancer cell lines were incubated with 0.5 and 0.1 mM trastuzumab, respectively, for 5 days. Incubation of breast cancer cells with trastuzumab led to decreased HER2/neu function, as indicated by decreased phosphorylation of the Tyr 1248 residue in the HER2/neu protein and decreased phosphorylation of the Ser 473 residue in the Akt protein (Figure 1b) . Blocking HER2/neu led to WT1 protein levels decreased by 51 and 43% in SKBr3 and BT-474 cells, respectively (Figure 1b) . Reduced WT1 protein expression in SKBr3 cells was also observed after 3 days incubation with the trastuzumab antibody (Figure 1b) . These data indicate that HER2/neu increases WT1 protein levels.
HER2/neu engages Akt to increase WT1 protein expression
Akt is an important downstream signaling protein of HER2/neu (Zhou et al., 2000; Lenferink et al., 2001) . To determine whether HER2/neu engages Akt to regulate WT1 expression, SKBr3 and BT-474 cells were incubated with an Akt inhibitor. As expected, the Akt inhibitor decreased the phosphorylation of the Ser 9 residue of GSK-3b, a downstream protein of Akt. The Akt inhibitor decreased WT1 protein expression in SKBr3 and BT-474 cells (Figure 2a) . By 72 h, the Akt inhibitor decreased WT1 levels by 45 and 61% in SKBr3 and BT-474 cells, respectively. To further confirm that Akt is involved in the regulation of WT1 expression, the levels of WT1 protein were compared between MDA-MB-453 wild-type cells and MDA-MB-453 cells stably transfected with the dominant-negative Akt mutant cDNA (DN-Akt) (Zhou et al., 2000) . Approximately two fold higher levels of WT1 protein were observed in MDA-MB-453 wild-type cells than in DN-Akt cells ( Figure 2b ). These data indicate that Akt is vital for the increased WT1 expression in HER2/neu-overexpressing cells.
Downregulation of WT1 protein expression induces cell cycle arrest and apoptosis in HER2/neu-overexpressing breast cancer cells
Previously, we demonstrated that WT1 protein is vital for the growth of BT-474 and SKBr3 cells, since downregulation of WT1 protein expression by liposome-incorporated WT1 (L-WT1) antisense oligos led to growth inhibition in both cell lines (Zapata-Benavides et al., 2002) . However, it is not known in which phase of the cell cycle WT1 is involved. BT-474 cells were incubated with L-WT1 antisense oligos and liposomal control (L-control) oligos for 5 days. Flow-cytometric analysis was used to determine which phase of the cell cycle WT1 is involved. In BT-474 cells, L-WT1 antisense oligos increased the percentage of cells in the G1 phase by 16%, and decreased the percentage of cells in the S phase by 15%. L-WT1 antisense oligos also increased the percentage of BT-474 apoptotic cells, as indicated by the sub-G1 phase, from 2.2 to 37.8% (Figure 3) . However, L-WT1 antisense oligos did not affect the RT-PCR was used to determine the effects of WT1 downregulation on cyclin D1 and bcl-2 mRNA levels. b-Actin was used as loading control. Total RNA was isolated by the TRIzol Reagent (Invitrogen, Carlsbad, CA, USA). cDNA was created with Superscript II (Invitrogen). All PCR reactions were carried out with 5 ml cDNA, 0.2 mM dNTPs, 2.5 mM of each primer, 10 mM Tris-HCl (pH 8.4, 50 mM KCl, 0.01% gelatin, 2.0 mM MgCl 2 ), and 2.5 U Taq DNA polymerase. The sequences of the cyclin D1 primers were: forward, 5 0 -CTG GAG CCC GTG AAA AGA GC-3 0 and reverse, 5 0 -CTG GAG GAA GCG TGT GAG G-3 0 . The sequences of the Bcl-2 primers were: forward, 5 0 -TGC ACC TGA CGC CCT TCA C-3 0 and reverse, 5 0 -AGA CAG CCA GGA GAA ATC AAA CAG-3 0 . The sequences of the b-actin primers were: forward, 5 0 -GTC ACC AAC TGG GAC GAC ATG-3 0 and reverse, 5 0 -GAC AGC ACT GTG TTG GCG TAC-3 0 . The PCR conditions for cyclin D1 were: 941C for 3 min, five cycles of 941C for 30 s and 721C for 45 s, 25 cycles of 941C for 30 s, 561C for 1 min and 721C for 2 min, followed by 7 min at 721C. Identical PCR conditions were used for Bcl-2, except that 30 cycles were used. The PCR conditions for b-actin were 941C for 5 min, and 30 cycles at 941C for 30 s, 551C for 30 s and 721C for 45 s, followed by 7 min at 721C. PCR products, subjected to electrophoresis on 1% agarose gels, were visualized with ethidium bromide and photographed under UV transillumination Role of WT1 in HER2-overexpressing cells M Tuna et al G2/M phase. Under the same conditions, L-control oligos did not affect the cell cycle distribution (Figure 3) . Similar effects were observed in SKBr3 cells. L-WT1 antisense oligos increased the percentage of SKBr3 cells in the G1 phase by 10%, but did not affect the G2/M phase (data not shown). L-WT1 antisense oligos also increased the percentage of SKBr3 cells undergoing apoptosis from 5.9 to 10.7% (data not shown). These data indicate that WT1 stimulates G1-to S-phase cell cycle progression and inhibits apoptosis in HER2/neuoverexpressing breast cancer cells.
WT1 protein regulates cyclin D1 and Bcl-2 expression at the transcription level
We then determined which cell cycling and apoptotic proteins may be regulated by WT1. Cyclin D1 is a downstream target of HER2/neu, and is essential for HER2/neu to induce mammary tumorigenesis in transgenic mice (Lee et al., 2000; Lenferink et al., 2001) . The expression of bcl-2 and WT1 mRNA is significantly correlated in leukemic blasts and is associated with reduced survival in patients with acute myelogenous leukemia (Karakas et al., 2002) . One possible mechanism by which WT1 prevents cells from undergoing apoptosis is by upregulating the antiapoptotic bcl-2 gene. Western blot was performed on untreated BT-474 cells and those treated with liposomal oligos and empty liposomes. L-WT1 antisense oligos inhibited WT1 protein expression by 50% (Figure 4a ), whereas Lcontrol oligos and empty liposomes did not affect WT1 protein expression (Figure 4a ). Downregulation of WT1 protein expression led to decreased cyclin D1 and Bcl-2 protein levels ( Figure 4a ). WT1 has been shown to increase bcl-2 transcription (Mayo et al., 1999) . We speculate that WT1 regulates cyclin D1 transcriptionally because the cyclin D1 promoter contains CG-rich elements that are potential WT1 consensus sequences. To determine whether WT1 regulates bcl-2 and cyclin D1 transcriptionally, treated and untreated BT-474 cells were subjected to RT-PCR. L-control oligos and empty liposomes did not have any effects on bcl-2 and cyclin D1 levels (Figure 4b) . Downregulation of WT1 protein expression by L-WT1 antisense oligos led to decreased bcl-2 and cyclin D1 mRNA levels (Figure 4b ).
Our finding that WT1 upregulates the transcription of the bcl-2 gene agrees with that of Mayo et al. (1999) .
However, the bcl-2 promoter has also been shown to be negatively regulated by WT1 (Hewitt et al., 1995; Cheema et al., 2003) . Differences in cell types, status of WT1 isoforms, and the interaction of WT1 protein with other proteins may explain the differences between our results and those of Hewitt et al. (1995) and Cheema et al. (2003) .
Our finding is the first to show that WT1 increases cyclin D1 mRNA levels, and that, in addition to Akt (Lenferink et al., 2001) , WT1 is another mechanism by which HER2/neu stimulates cyclin D1 expression. The activation of Akt leads to increased cell growth and survival by phosphorylating and inactivating some of the downstream targets such as BAD (Datta et al., 1996) , pro-caspase 9 (Cardone et al., 1998) , GSK3-b (Gold et al., 1999; Takata et al., 1999) , and forkhead transcription factors (Brunet et al., 1999) . Akt activates downstream proteins by phosphorylating them at the consensus sequence site (RXRXXS). Since an Akt consensus site cannot be found within the WT1 sequence, Akt is likely to increase WT1 levels via other downstream factors.
Previously, we showed that 17b-estradiol increased WT1 protein expression in ER-positive breast cancer cells (Zapata-Benavides et al., 2002) . Here, we report that HER2/neu increases WT1 levels, and that WT1 has a key role in mediating proliferative and antiapoptotic effects in HER2/neu-overexpressing cells, possibly by regulating the transcription of cyclin D1 and bcl-2. Our data support earlier observations that WT1 may play a vital role in the aggressive phenotypes of breast cancer cells . WT1 may be used as a novel therapeutic target in HER2/neu-overexpressing breast cancer.
